Lexicon Pharmac.
Lexicon Pharmaceuticals develops orally delivered small‑molecule drugs for heart failure, diabetes, and obesity, with Phase III Sotagliflozin and promising pipeline assets LX9211 and LX9851. Key collaborations with Bristol‑Myers Squibb boost market access.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 103
- HQ: The Woodlands
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.